FDA Grants Approval for Atropine Sulfate ANDA219996
The FDA has granted approval for ANDA219996, a generic version of Atropine Sulfate, submitted by Gland.
Published: August 5, 2026
Updated: August 5, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Anticholinergic
Asset: Gland
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Gland
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Gland's generic Atropine Sulfate introduces significant competition in the cardiovascular market. This could impact pricing and market share for existing branded products, necessitating strategic adjustments from portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies from Gland and competitors.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.